There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD – Research Report) and Clene (CLNN – Research Report) with bullish sentiments.
Clene (CLNN)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Clene, with a price target of $7.00. The company’s shares closed last Wednesday at $0.39, close to its 52-week low of $0.25.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clene with a $4.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PYPD:
- PolyPid Advances Phase 3 Trial, Strengthens Finances
- PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PolyPid to Participate in Citizens JMP Life Sciences Conference
- PolyPid Advances Phase 3 Trial, Eyes Future Funding
- PolyPid announces enrollment in 200th patient in SHIELD II Phase 3 trial
